• Sandoz advances biosimilar portfolio with sixth major biosimilar file acceptance in less than one year

• Sandoz is seeking approval for all indications included in the reference product’s label

• Sandoz’ submission includes data from multiple clinical trials with over 800 patients

Holzkirchen, 24 May, 2016 – Sandoz, a Novartis division and the global leader in biosimilars, announced today that the European Medicines Agency has accepted their Marketing Authorization Application for a biosimilar to Roche’s EU-licensed …